ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Kiniksa Announces Issuance of U.S. Patent for Treatment of Recurrent Pericarditis
June 09, 2021Kiniksa Pharmaceuticals, Ltd. today announced that the U.S Patent and Trademark Office issued a patent covering methods of using ARCALYST® (rilonacept) in the treatment of recurrent pericarditis. -
FDA nod for Kiniksa’s Arcalyst in recurrent pericarditis
March 22, 2021The US Food and Drug Administration (FDA) has approved Kiniksa Pharmaceuticals’ interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) inhibitor Arcalyst (rilonacept) for the treatment of recurrent pericarditis and reduction in risk of recurrence ...
Pharma Sources Insight January 2025
